Therapeutic Advances in Medical Oncology
@tamedoncol.bsky.social
A SAGE Publishing Gold #openaccess journal | Publishing innovative clinically focused articles on the medical treatment of cancer| PubMed Indexed | IF: 4.3
Many breast cancer survivors face diminished quality of life due to estrogen deprivation.
This review provides updated guidance on vulvovaginal health, safe treatments, and strategies to support endocrine therapy adherence. Full article 👉 buff.ly/RmCbexo #CancerResearch #BreastCancer #Survivorship
This review provides updated guidance on vulvovaginal health, safe treatments, and strategies to support endocrine therapy adherence. Full article 👉 buff.ly/RmCbexo #CancerResearch #BreastCancer #Survivorship
November 20, 2025 at 8:15 AM
Many breast cancer survivors face diminished quality of life due to estrogen deprivation.
This review provides updated guidance on vulvovaginal health, safe treatments, and strategies to support endocrine therapy adherence. Full article 👉 buff.ly/RmCbexo #CancerResearch #BreastCancer #Survivorship
This review provides updated guidance on vulvovaginal health, safe treatments, and strategies to support endocrine therapy adherence. Full article 👉 buff.ly/RmCbexo #CancerResearch #BreastCancer #Survivorship
🔬 CDK4/6 inhibitors have transformed HR+ MBC care - but resistance is a growing challenge.
This review explores the molecular drivers and emerging strategies to counteract them. Full article 👉 buff.ly/1YracNB #CancerResearch #Oncology
This review explores the molecular drivers and emerging strategies to counteract them. Full article 👉 buff.ly/1YracNB #CancerResearch #Oncology
November 17, 2025 at 8:15 AM
🔬 CDK4/6 inhibitors have transformed HR+ MBC care - but resistance is a growing challenge.
This review explores the molecular drivers and emerging strategies to counteract them. Full article 👉 buff.ly/1YracNB #CancerResearch #Oncology
This review explores the molecular drivers and emerging strategies to counteract them. Full article 👉 buff.ly/1YracNB #CancerResearch #Oncology
🔬 New insights into HER2-low TNBC: • 47.7% of Asian TNBC patients classified as HER2-low • Distinct genomic profile (↓ BRCA1, ↑ PIK3CA) • No difference in survival outcomes vs HER2-zero
Full study 👉 buff.ly/kXKMwn8 #BreastCancer #HER2 #CancerResearch
Full study 👉 buff.ly/kXKMwn8 #BreastCancer #HER2 #CancerResearch
November 13, 2025 at 8:15 AM
🔬 New insights into HER2-low TNBC: • 47.7% of Asian TNBC patients classified as HER2-low • Distinct genomic profile (↓ BRCA1, ↑ PIK3CA) • No difference in survival outcomes vs HER2-zero
Full study 👉 buff.ly/kXKMwn8 #BreastCancer #HER2 #CancerResearch
Full study 👉 buff.ly/kXKMwn8 #BreastCancer #HER2 #CancerResearch
Could the clock be a treatment factor? This retrospective study of 248 patients with mGC found better survival outcomes when nivolumab was infused before mid-afternoon.
Authors suggest infusion timing should be considered in daily practice. Details here: buff.ly/k54we7o
Authors suggest infusion timing should be considered in daily practice. Details here: buff.ly/k54we7o
November 10, 2025 at 9:21 AM
Could the clock be a treatment factor? This retrospective study of 248 patients with mGC found better survival outcomes when nivolumab was infused before mid-afternoon.
Authors suggest infusion timing should be considered in daily practice. Details here: buff.ly/k54we7o
Authors suggest infusion timing should be considered in daily practice. Details here: buff.ly/k54we7o
📢 Call for Papers!
Submit to our special issue: “Geriatric Oncology: Advancing Cancer Care in an Aging World” buff.ly/ASkDwOt
🗓️ Join the conversation on cancer care for older adults.
#GeriatricOncology #CancerResearch #Oncology #CallForPapers #MedicalPublishing
Submit to our special issue: “Geriatric Oncology: Advancing Cancer Care in an Aging World” buff.ly/ASkDwOt
🗓️ Join the conversation on cancer care for older adults.
#GeriatricOncology #CancerResearch #Oncology #CallForPapers #MedicalPublishing
November 1, 2025 at 7:15 AM
📢 Call for Papers!
Submit to our special issue: “Geriatric Oncology: Advancing Cancer Care in an Aging World” buff.ly/ASkDwOt
🗓️ Join the conversation on cancer care for older adults.
#GeriatricOncology #CancerResearch #Oncology #CallForPapers #MedicalPublishing
Submit to our special issue: “Geriatric Oncology: Advancing Cancer Care in an Aging World” buff.ly/ASkDwOt
🗓️ Join the conversation on cancer care for older adults.
#GeriatricOncology #CancerResearch #Oncology #CallForPapers #MedicalPublishing
In non-metastatic HER2− #BreastCancer, NCDB data (2018) showed higher pCR rates with neoadjuvant chemo in HR-Low vs HR-High groups. HR-Low tumors had higher grade/stage and lower endocrine therapy use, underscoring need for clearer treatment guidance.
🔗 journals.sagepub.com/doi/epdf/10....
🔗 journals.sagepub.com/doi/epdf/10....
October 10, 2025 at 3:59 PM
In non-metastatic HER2− #BreastCancer, NCDB data (2018) showed higher pCR rates with neoadjuvant chemo in HR-Low vs HR-High groups. HR-Low tumors had higher grade/stage and lower endocrine therapy use, underscoring need for clearer treatment guidance.
🔗 journals.sagepub.com/doi/epdf/10....
🔗 journals.sagepub.com/doi/epdf/10....
In HR+ advanced #BreastCancer progressing after CDK4/6 inhibitors, network meta-analysis (19 RCTs; n=6621) found CDK4/6i + fulvestrant most effective for PFS, especially in visceral metastases or ESR1 mutations; Bcl-2i + Ful and SERDs also showed benefit
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
October 10, 2025 at 3:57 PM
In HR+ advanced #BreastCancer progressing after CDK4/6 inhibitors, network meta-analysis (19 RCTs; n=6621) found CDK4/6i + fulvestrant most effective for PFS, especially in visceral metastases or ESR1 mutations; Bcl-2i + Ful and SERDs also showed benefit
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
In HER2+ salivary duct carcinoma, trastuzumab-deruxtecan (T-Dxd) achieved 13 months of disease control in a multitreated 44-year-old patient, supporting further study of anti-HER2 therapy in rare salivary tumors.
🔗 journals.sagepub.com/doi/epdf/10....
#HER2 #SalivaryCancer #Oncology
🔗 journals.sagepub.com/doi/epdf/10....
#HER2 #SalivaryCancer #Oncology
October 10, 2025 at 3:54 PM
In HER2+ salivary duct carcinoma, trastuzumab-deruxtecan (T-Dxd) achieved 13 months of disease control in a multitreated 44-year-old patient, supporting further study of anti-HER2 therapy in rare salivary tumors.
🔗 journals.sagepub.com/doi/epdf/10....
#HER2 #SalivaryCancer #Oncology
🔗 journals.sagepub.com/doi/epdf/10....
#HER2 #SalivaryCancer #Oncology
In HER2-mutated non-small-cell lung cancer, combination regimens achieved markedly better outcomes than single-agent approaches.
Median PFS: 7.8 vs 5.3 mo; best results seen with chemo + immunotherapy + anti-angiogenic therapy.
🔗 journals.sagepub.com/doi/epdf/10....
Median PFS: 7.8 vs 5.3 mo; best results seen with chemo + immunotherapy + anti-angiogenic therapy.
🔗 journals.sagepub.com/doi/epdf/10....
October 10, 2025 at 3:51 PM
In HER2-mutated non-small-cell lung cancer, combination regimens achieved markedly better outcomes than single-agent approaches.
Median PFS: 7.8 vs 5.3 mo; best results seen with chemo + immunotherapy + anti-angiogenic therapy.
🔗 journals.sagepub.com/doi/epdf/10....
Median PFS: 7.8 vs 5.3 mo; best results seen with chemo + immunotherapy + anti-angiogenic therapy.
🔗 journals.sagepub.com/doi/epdf/10....
In patients with metastatic #gastriccancer, earlier nivolumab monotherapy infusions (before 14:00) were associated with significantly longer PFS and OS (7.6 vs 3.9 mo). Authors suggest infusion timing may influence outcomes in #Immunotherapy practice.
🔗 journals.sagepub.com/doi/epdf/10....
🔗 journals.sagepub.com/doi/epdf/10....
October 10, 2025 at 3:48 PM
In patients with metastatic #gastriccancer, earlier nivolumab monotherapy infusions (before 14:00) were associated with significantly longer PFS and OS (7.6 vs 3.9 mo). Authors suggest infusion timing may influence outcomes in #Immunotherapy practice.
🔗 journals.sagepub.com/doi/epdf/10....
🔗 journals.sagepub.com/doi/epdf/10....
Ontario study of OHIP data (2015–2022): female cancer diagnostic billing dropped in 2020 (cervical −50.7/100k, breast −13.9/100k) but rebounded sharply in 2021–22, with net excesses across all cancer types. COVID-19 disruptions drove delayed diagnoses.
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
October 3, 2025 at 2:53 PM
Ontario study of OHIP data (2015–2022): female cancer diagnostic billing dropped in 2020 (cervical −50.7/100k, breast −13.9/100k) but rebounded sharply in 2021–22, with net excesses across all cancer types. COVID-19 disruptions drove delayed diagnoses.
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
Phase III FLINTER trial (N=317) shows rituximab biosimilar DRL_RI is equivalent to MabThera® in untreated low–tumor-burden follicular lymphoma: BORR 80.2% vs 79.4% (Δ0.9%, CI within ±17%). Safety, immunogenicity, PK/PD profiles comparable. #Lymphoma
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
October 3, 2025 at 2:52 PM
Phase III FLINTER trial (N=317) shows rituximab biosimilar DRL_RI is equivalent to MabThera® in untreated low–tumor-burden follicular lymphoma: BORR 80.2% vs 79.4% (Δ0.9%, CI within ±17%). Safety, immunogenicity, PK/PD profiles comparable. #Lymphoma
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
Study of 2896 early-stage #BreastCancer pts: CanAssist Breast prognostic test stratified ER1–20% subgroup. 65% classified low risk with 91% DRFI, 35% high risk with 61% DRFI. CAB may guide tailored therapy beyond ER levels in this challenging group.
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
October 3, 2025 at 2:50 PM
Study of 2896 early-stage #BreastCancer pts: CanAssist Breast prognostic test stratified ER1–20% subgroup. 65% classified low risk with 91% DRFI, 35% high risk with 61% DRFI. CAB may guide tailored therapy beyond ER levels in this challenging group.
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
Propensity-matched study (n=127) in extensive-stage #SCLC after first-line chemoimmunotherapy: prophylactic cranial irradiation (PCI) did not improve OS overall but reduced brain metastases (1-yr 13.8% vs 53.4%). OS benefit seen in partial responders.
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
October 3, 2025 at 2:48 PM
Propensity-matched study (n=127) in extensive-stage #SCLC after first-line chemoimmunotherapy: prophylactic cranial irradiation (PCI) did not improve OS overall but reduced brain metastases (1-yr 13.8% vs 53.4%). OS benefit seen in partial responders.
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
Systematic review & network meta-analysis in advanced EGFR-mutated #NSCLC after TKI failure: chemo+ivonescimab ranked best for PFS with acceptable safety; chemo+amivantamab gave strongest OS/ORR but higher toxicity. Chemo+IO or chemo alone less effective.
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
October 3, 2025 at 2:47 PM
Systematic review & network meta-analysis in advanced EGFR-mutated #NSCLC after TKI failure: chemo+ivonescimab ranked best for PFS with acceptable safety; chemo+amivantamab gave strongest OS/ORR but higher toxicity. Chemo+IO or chemo alone less effective.
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
Phase IV CoVigi trial: in 204 pts with solid #cancer on therapy, 92% developed anti-S antibodies after 2nd BNT162b2 dose; all seroconverted by 6 mo. Chemotherapy impaired both humoral & cellular responses, while prior COVID-19 infection boosted immunity.
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
September 26, 2025 at 2:47 PM
Phase IV CoVigi trial: in 204 pts with solid #cancer on therapy, 92% developed anti-S antibodies after 2nd BNT162b2 dose; all seroconverted by 6 mo. Chemotherapy impaired both humoral & cellular responses, while prior COVID-19 infection boosted immunity.
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
Multicenter Mexican cohort (n=477) of young women with #BreastCancer (≤40 yrs): 62% followed a poor long-term QoL trajectory over 5 yrs, with declines in sexual health & future perspective. HER2+ status & public insurance linked to better QoL outcomes.
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
September 26, 2025 at 2:45 PM
Multicenter Mexican cohort (n=477) of young women with #BreastCancer (≤40 yrs): 62% followed a poor long-term QoL trajectory over 5 yrs, with declines in sexual health & future perspective. HER2+ status & public insurance linked to better QoL outcomes.
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
Retrospective study of 110 high-risk rectal cancer pts: total neoadjuvant therapy achieved organ preservation in ~50% with 3-yr DFS 75.7% OS 92.4%. Watch & wait strategy gave superior outcomes vs non-pCR pts. TNT supports durable survival & bowel function
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
September 26, 2025 at 2:44 PM
Retrospective study of 110 high-risk rectal cancer pts: total neoadjuvant therapy achieved organ preservation in ~50% with 3-yr DFS 75.7% OS 92.4%. Watch & wait strategy gave superior outcomes vs non-pCR pts. TNT supports durable survival & bowel function
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
Study in advanced #GastricCancer: flow cytometry of peritoneal lavage showed CD44+/CD326+ tumor cells correlate with response to repeated intraperitoneal perfusion chemotherapy (RIPPENC). Lower levels linked to resection eligibility & longer survival.
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
September 26, 2025 at 2:42 PM
Study in advanced #GastricCancer: flow cytometry of peritoneal lavage showed CD44+/CD326+ tumor cells correlate with response to repeated intraperitoneal perfusion chemotherapy (RIPPENC). Lower levels linked to resection eligibility & longer survival.
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
Phase Ib study of xevinapant + avelumab in advanced solid tumours & #NSCLC: RP2D established at 200 mg/day, safety manageable. In NSCLC (n=38), ORR 10.5% (not superior to avelumab alone). Biomarker analyses highlight immune signatures tied to response
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
September 18, 2025 at 12:22 PM
Phase Ib study of xevinapant + avelumab in advanced solid tumours & #NSCLC: RP2D established at 200 mg/day, safety manageable. In NSCLC (n=38), ORR 10.5% (not superior to avelumab alone). Biomarker analyses highlight immune signatures tied to response
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
Systematic review & meta-analysis (9 RCTs) in advanced gastric cancer: #immunotherapy + chemo did not improve OS/PFS vs chemo alone in pts with low PD-L1 (CPS<1 or <5). Dual antibody regimens showed PFS benefit (HR 0.64), warranting further study.
Read: journals.sagepub.com/doi/epdf/10....
Read: journals.sagepub.com/doi/epdf/10....
September 18, 2025 at 12:18 PM
Systematic review & meta-analysis (9 RCTs) in advanced gastric cancer: #immunotherapy + chemo did not improve OS/PFS vs chemo alone in pts with low PD-L1 (CPS<1 or <5). Dual antibody regimens showed PFS benefit (HR 0.64), warranting further study.
Read: journals.sagepub.com/doi/epdf/10....
Read: journals.sagepub.com/doi/epdf/10....
Retrospective study of 213 late-stage cancer pts in Jordan evaluates #NGS. Clinically significant alterations in 42% (KRAS, PIK3CA, ERBB2, EGFR, BRCA). PFS markedly improved with NGS-guided therapy (HR 0.216) though cost & drug access remain major barriers
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
September 18, 2025 at 12:10 PM
Retrospective study of 213 late-stage cancer pts in Jordan evaluates #NGS. Clinically significant alterations in 42% (KRAS, PIK3CA, ERBB2, EGFR, BRCA). PFS markedly improved with NGS-guided therapy (HR 0.216) though cost & drug access remain major barriers
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
In NSCLC patients with bone metastases, those receiving palliative RT during ICI treatment had significantly better survival: median OS 16 mo vs 3 mo; PFS also improved.
These findings support a synergistic role for RT with immunotherapy.
🔗 journals.sagepub.com/doi/epdf/10....
These findings support a synergistic role for RT with immunotherapy.
🔗 journals.sagepub.com/doi/epdf/10....
May 16, 2025 at 5:50 PM
In NSCLC patients with bone metastases, those receiving palliative RT during ICI treatment had significantly better survival: median OS 16 mo vs 3 mo; PFS also improved.
These findings support a synergistic role for RT with immunotherapy.
🔗 journals.sagepub.com/doi/epdf/10....
These findings support a synergistic role for RT with immunotherapy.
🔗 journals.sagepub.com/doi/epdf/10....
In real-world data from 147 advanced BTC patients refractory to gem/cis, second-line 5-FU-based therapy showed modest survival (median OS 4.8 mo).
FOLFOX had comparable efficacy but better safety than Nal-IRI/FL or FOLFIRINOX—supporting role as 2L option.
journals.sagepub.com/doi/epdf/10....
FOLFOX had comparable efficacy but better safety than Nal-IRI/FL or FOLFIRINOX—supporting role as 2L option.
journals.sagepub.com/doi/epdf/10....
May 16, 2025 at 5:49 PM
In real-world data from 147 advanced BTC patients refractory to gem/cis, second-line 5-FU-based therapy showed modest survival (median OS 4.8 mo).
FOLFOX had comparable efficacy but better safety than Nal-IRI/FL or FOLFIRINOX—supporting role as 2L option.
journals.sagepub.com/doi/epdf/10....
FOLFOX had comparable efficacy but better safety than Nal-IRI/FL or FOLFIRINOX—supporting role as 2L option.
journals.sagepub.com/doi/epdf/10....
New real-world data from China compares flumatinib vs nilotinib as 1L treatment for chronic phase CML (n=165):
🔹 Similar MMR at 12 mo (85.1% vs 88.2%)
🔹 Nilotinib led to higher MR4 at all timepoints
🔹 Flumatinib had fewer metabolic/liver AEs
🔗 journals.sagepub.com/doi/epdf/10....
🔹 Similar MMR at 12 mo (85.1% vs 88.2%)
🔹 Nilotinib led to higher MR4 at all timepoints
🔹 Flumatinib had fewer metabolic/liver AEs
🔗 journals.sagepub.com/doi/epdf/10....
May 13, 2025 at 5:01 PM
New real-world data from China compares flumatinib vs nilotinib as 1L treatment for chronic phase CML (n=165):
🔹 Similar MMR at 12 mo (85.1% vs 88.2%)
🔹 Nilotinib led to higher MR4 at all timepoints
🔹 Flumatinib had fewer metabolic/liver AEs
🔗 journals.sagepub.com/doi/epdf/10....
🔹 Similar MMR at 12 mo (85.1% vs 88.2%)
🔹 Nilotinib led to higher MR4 at all timepoints
🔹 Flumatinib had fewer metabolic/liver AEs
🔗 journals.sagepub.com/doi/epdf/10....